{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/jennifer-r-brown/", "hostname": "dana-farber.org", "description": "Jennifer R. Brown, MD, PhD - Medical Oncology. Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular bio...", "sitename": "Jennifer R. Brown, MD, PhD - Dana-Farber Cancer Institute", "date": "2013-05-15", "cleaned_text": "Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023 Aug 24; 142(8):687-699. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37390310) Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient Blood. 2023 View May 04; 388(18):1720-1721. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37133597) METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. Blood Cancer Discov. 2023 05 01; 4(3):228-245. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37067905) Treatment Discontinuation for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors. Blood Cancer J. 2023 02 02; 13(1):22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36732326) A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2023 04; 37(4):835-842. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36624313) PI3K inhibitors in 108(1):9-21. Refractory Chronic Leukemia. N Engl J Med. 2023 01 26; 388(4):319-332. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36511784) initial Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Clin Oncol. 2023 02 10; 41(5):1035-1045. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36395435) Resistance to PI3Kd inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Development of Lymphocytic Leukemia. Clin Oncol. 2023 02 10; 41(5):1116-1128. Characterize PI3K Inhibitor Responses in Chronic Lymphocytic map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. in: of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Front Oncol. small lymphocytic lymphoma in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35810754) Response to \"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: View patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis from the lymphoma cohort in a regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic 197(2):207-211. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35170759) Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: \"What's Past Is Prologue\" (Shakespeare). in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34788401) Allogeneic 12 and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror 2021 12 Managing Practice. Front Oncol. 11:720704. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34858810) A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of single-arm, phase in chronic lymphocytic leukemia axis is and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 81(24):6117-6130. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34534514) 08 24; 5(16):3062-3065. View The future antibody therapy lymphocytic 2021 12; 62(12):2915-2920. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34319205) with CLL receiving bendamustine plus mediates resistance to PI3K inhibitors in chronic Blood. 2021 07 08; 138(1):44-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33684943) Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Evolving Use Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. Oncol. 2021; 11:640731. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34113563) Chronic leukemia by targeting TRAF4: an axis affected by Blood. 2021 05 06; 137(18):2481-2494. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33171493) Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in Cell Cell Cell Dev Biol. 2021; 9:648925. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33898440) High-grade Jun; 7(6):391-394. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34194987) A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. 2021 trial of the inhibitor [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33373063) Mechanism of use. Nature. 2021 02; 590(7844):157-162. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33361812) Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020 12 17; Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33604581) A prospective study of minimal residual disease in patients with diffuse large B-cell deletion. Haematologica. 2020 10 13; 106(9):2354-2363. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33054121) Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl 2020 09 16; 12(561). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32938797) Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32882002) Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 09 03; 136(10):1134-1143. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32688395) Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32841336) A study of duvelisib in combination with FCR (DFCR) for frontline therapy for CLL patients. Leukemia. 2021 04; 35(4):1064-1072. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32820271) How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. Hemasphere. 2020 Aug; 4(4):e432. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32803132) Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with Leukemia. 2020 12; in CLL patients treated with BTK inhibitors. chronic lymphocytic updated phase 2 results. 10; 4(5):858-867. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32126141) Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. Evolving Strategies in First-Line Chronic Nov/Dec; 25(6):394-400. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31764120) Ibrutinib-associated invasive non-Hodgkin View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31520441) Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31543463) For CLL cells, Lymphoma. 2019 12; 60(14):3347-3349. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31373247) Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in With Del(11q) assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 08 22; 134(8):688-698. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31292113) Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; plus fludarabine, cyclophosphamide, and initial younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase Aug; 6(8):e419-e428. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31208944) Growth dynamics 06; 570(7762):474-479. in patients with lymphocytic leukemia intolerant to ibrutinib. Blood Adv. 2019 05 14; of lenalidomide, bendamustine, and rituximab in previously untreated patients with Leuk Lymphoma. 2019 12; 60(12):2931-2938. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31074316) results a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic 04 09; 3(7):1167-1174. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30967392) Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30767298) Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 02 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30593446) Umbralisib in combination with patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. Br J Haematol. 2019 03; 184(6):925-936. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30537114) Oncol. 2019 01; 20(1):3-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30522966) Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br Haematol. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30506764) Patients with CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30501481) Relapsed CLL: 2018 11 30; 2018(1):248-255. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30504318) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018 12 10; PI3K p110d inactivation antagonizes chronic leukemia and reverses T cell immune suppression. J Clin Invest. 2019 01 02; 129(1):122-136. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30457982) high alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for deleted of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With in: or chronic lymphocytic leukaemia: based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One. 2018; 13(3):e0193249. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29513759) Are BTK and PLCG2 mutations and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018 03; 11(3):185-194. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29381098) Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Adv Biosyst. 2018 Feb; 2(2). Blood. 2018 01 25; 131(4):379-386. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29255067) The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. Oncologist. 2018 03; 23(3):288-296. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29212732) Experience 2018 Jan; by View germ in 11 in: fibrillation Chemoimmunotherapy with who have comorbidities - is single-cell analysis suggests novel of chronic leukemia. Genome Res. 2017 34(7):509-527. View in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic combination of BCL-2 inhibitors and ibrutinib as frontline therapy in [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28388253) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615. View in: safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an 2017 02 23; 542(7642):489-493. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28199309) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27815263) Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27818134) Ibrutinib efficacy and tolerability with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2117-2125. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27660167) for chronic with 17p deletion (RESONATE-17): 2017 Feb 01; 23(3):735-745. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27503198) Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-d/? Inhibitors. ACS Med Chem Lett. B cells by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27480113) FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83. in: A phase study of bendamustine and rituximab in chronic lymphocytic 2017 09; chronic lymphocytic causes frequent immune-mediated hepatotoxicity. Blood. inhibition blocks critical in 2016 07 28; 128(4):574-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27235137) Clonal evolution in determinant by mutated MYD88, and a direct target 2016 rapid onset apoptosis of CLL cells in patients via a TP53-independent study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell 2016 Apr; 173(1):89-95. View Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? Am Soc 2016 Jan 28; 374(4):323-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26641137) Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl 10(11):e0143685. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26606677) of surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open. 2015 Oct 06; 5(10):e008350. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26443656) A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed lymphocytic leukemia. Leuk Lymphoma. 2015; inhibition in chronic pursuit Lymphocytic Case for Chemotherapy. Oncology (Williston cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26032737) Management of adverse Pilaralisib Obinutuzumab plus of CLL patients: the phase 1b GALTON trial. Blood. 2015 May 07; 125(19):2915-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25755291) Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25804339) Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015 Feb; 75(2):143-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25619739) Locally disordered methylation of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 08; 26(6):813-825. study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25012943) A novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014 Oct; 167(2):149-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25040077) Genetic variation lymphoma. PLoS One. 2014; 9(7):e101685. View in: in cancer a covalent Nature. 2014 chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the RESONATE 2014 Jun 20; 32(18_suppl):LBA7008. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28141976) incidence and associated risk factors in an inner-city population. J Card Fail. 2014 Aug; previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; of human Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24868078) Lenalidomide and rituximab for the of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic research consortium. Oncol. 2014 Jul 01; as a mechanism of Wnt/\u00df-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98. in: chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014 Mar 15; a selective inhibitor as therapy for previously treated indolent lymphoma. Blood. 2014 May 29; 123(22):3406-13. View in: phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle 123(22):3390-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24615777) Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7. View cell [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27471698) Novel treatments leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014; e317-25. View in: Lancet Oncol. 2014 Jan; 15(1):3-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24332240) Does total body outcomes of leukocyte antigen-identical sibling transplantations Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic follicular lymphoma: a systematic review and meta-analysis. Clin 01; 19(23):6566-77. View in: Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23912587) Inherited susceptibility to chronic lymphocytic evidence and for the Aug; 4(4):298-308. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23926461) DNA patients with B-cell non-Hodgkin I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab View in: and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb clofarabine for lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321251) Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J in: enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23190424) Targeting the B cell receptor in chronic leukemia. Leuk 120(17):3501-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22955911) Long-term follow-up transplantation for chronic lymphocytic leukemia: prognostic model to predict PARP1 72(16):4193-203. at 8q24 in chronic lymphocytic Res. 2012 Jul 15; 18(14):3791-802. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22623730) Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012 Apr 01; 30(10):1072-9. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22393093) Risk development after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide 2012 53(6):1130-6. View chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J 2012 Feb 10; 30(5):488-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22184378) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 2011 Nov 01; 17(21):6702-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21918174) Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 2011 Jun 07; 154(11):727-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21646556) Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2605-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21427241) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin 2011 May 01; 17(9):2977-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21402714) MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 View situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21156226) Stimulation of lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Dec; 203(2):134-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21156225) Novel [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21326166) Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer. 2011 Apr 01; 117(7):1470-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21425148) B-cell and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol. 2010 Dec; 38(12):1167-77. and sporadic lymphocytic leukaemia using high resolution array comparative genomic subcutaneous treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. View acute lymphoblastic leukemia. Proc Natl Acad A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8. View in: prophylaxis Oct; 1(1):51-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19802369) Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. View and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow 2008 Apr; 14(4):418-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18342784) Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May and combination therapy in patients with syndrome or fludarabine-refractory chronic lymphocytic leukemia. In Press.. AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. J Clin Oncol. 2007 Jul 20; 25(21):3176-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17634499) after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17697968) Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with 2007; 110:951a. TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP70. Blood. 2007; 110:616a. A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL). Blood. 2007; 110:920a. A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas. Blood. 2007; 110:408a. Interim Safety and Efficacy Results from the Phase 2 Multicenter Study of Subcutaneous Alemtuzumab Combined with Fludarabine for Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. Blood. 2007; 110:227a. Prevalence of Familial Malignancy in a Prospectively Screened Cohort of Patients with CLL and Lymphoproliferative Presenting at the Insertion Site of a Peritoneal Dialysis Catheter. Journal of Clinical Oncology. 2007; 25:3176-3178. Relative Value of ZAP70, CD38 and Immunoglobulin Mutation Status in Predicting Disease Progression in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma. 2007; 48(Suppl 1):S90. Prospective Evaluation of FDG-PET Imaging Response in Relapsed Follicular Lymphoma. Blood. 2007; 110:689a. Phase II Trial of (Everolimus) in 110:4496a. Chronic lymphocytic leukemia requires BCL2 to sequester explaining sensitivity BCL2 Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. Blood. 2006; 108(11):786a. Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Lymphocytic of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse. Blood. 2006; 108(11):865a. Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. Blood. 2006; 108(11):785a. Combination of Oxaliplatin, Fludarabine, Blood. 2006; 108(11):799a. Prevalence of Familial Lymphoproliferative Malignancy in a Prospectively Screened Cohort of Patients with Lymphoproliferative Disorders. Blood. 2006; 108(11):246a. Self-Administered, Subcutaneous (SQ) Alemtuzumab To with CLL. Blood. 2006; 108(11):804a. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17084369) Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Journal of Clinical Oncology. 2006; 24(18S):6598. Differential Diagnosis. Canellos GP, Lister The Lymphomas. 2006; 158-66. Paraneoplastic Syndromes. Canellos The Lymphomas. 2006; 139-46. Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Blood. 2005; 106(11):601a. Paradoxical embolism after peripheral blood stem cell infusion. Bone Marrow Transplant. 2005 Sep; 36(6):561-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16007104) Chronic lymphocytic leukemia: 2005 Jun 01; 11(11):3971-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15930331) Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation Lymphomas. In: UpToDate, Rose, B.D. Hodgkin's Lymphomas. In: UpToDate, Rose, B.D. Ed. 2005. Secondary Solid Tumors after Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. American Journal of Oncology Review. B.D. Ed. lymphoma: CASE 2. Hodgkin's lymphoma of the Oct associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Clin Pathol. 2004 May; 121(5):701-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15266094) Small-cell cancers, unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J UpToDate, 2003. Challenges in the development of platelet growth factors: low expectations for low counts. C, Messersmith editors. The MGH Primer of Outpatient Medicine. 2002; 241-6. Anemia. Basch EM, Birnbaum SL, Garza C, Messersmith W, editors. The MGH Primer of Outpatient Medicine. 2002; 235-40. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in Haemost. 2001 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11434705) Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci. 1998 Sep 01; 18(17):6952-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9712664) Fos family members induce cell cycle entry by activating cyclin D1. of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci A. 1997 Sep 16; 94(19):10397-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9294222) A defect in nurturing in mice lacking the immediate early gene fosB. Cell. 1996 Jul 26; 86(2):297-309. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8706134) The Role of Fos Family Genes in Adaptive Neuronal Responses and Cell Proliferation [PhD Dissertation]. 1996. A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene. 1993 Apr; 8(4):899-907. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8455944) Gene Targeting of the c-Raf Proto-Oncogene [Master's Thesis]. 1990. "}